-+ 0.00%
-+ 0.00%
-+ 0.00%

Illumina Rolls Out TruPath Genome At $395

Benzinga·02/24/2026 17:20:29
Listen to the news

Illumina, Inc. (NASDAQ:ILMN) today announced the launch of TruPath™ Genome, setting a new standard for high-quality, comprehensive whole genome insights for genetic disease. TruPath Genome has been found to deliver unparalleled accuracy and resolution—even across so-called "dark regions" of the genome—providing researchers with a more complete picture of genomic alterations implicated in genetic disease.

TruPath Genome delivers a highly cost-effective whole genome workflow solution at a $395 USD list price.